Human albumin solutions, including hypo-/iso-oncotic (4–5%) or hyper-oncotic (20–25%) formulations, are administered to correct hypoalbuminemia and expand intravascular volumes [5,6,7]. This evidence concerns the gene ALB and Hypoalbuminemia.